Gilead Sciences Reports New Efficacy, Safety Results From Lenacapavir Trial For HIV Prevention

(RTTNews) - Gilead Sciences, Inc. (GILD), Wednesday announced full efficacy and safety results from its pivotal, Phase 3 PURPOSE 1 trial with lenacapavir, the company's twice-yearly injectable HIV-1 capsid inhibitor. https://www.nasdaq.com/articles/gilead-sciences-reports-new-efficacy-safety-results-lenacapavir-trial-hiv-prevention